Chaetomium Globosum

Dosage for Chaetomium globosum is highly individualized and must be determined by a specialist (usually an allergist or immunologist). There is no 'standard' dose due to the non-standardized nature of the extract.

Diagnostic Testing

• Prick-Puncture Test: Usually a concentration of 1:10 or 1:20 w/v or 10,000 to 20,000 PNU/mL. A single drop is applied to the skin, and the skin is pricked through the drop.
• Intradermal Test: If the prick test is negative, an intradermal injection of 0.02 mL to 0.05 mL of a much more dilute solution (e.g., 100 PNU/mL or 1:1000 w/v) may be administered.

Immunotherapy (Allergy Shots)

• Build-up Phase: Starts with a very low dose (e.g., 0.05 mL of a 1:100,000 w/v dilution). Injections are given 1-2 times per week, with the dose increasing by 25% to 50% each time, provided no significant local reactions occur.
• Maintenance Phase: Once the 'top dose' is reached (the highest dose the patient tolerates without systemic reactions), the interval between injections is increased to every 2-4 weeks. A typical maintenance dose might be 0.5 mL of a 1:100 or 1:20 w/v solution.

Chaetomium globosum is generally considered safe for use in children, though the decision to start immunotherapy is based on the child's maturity and the severity of their symptoms.

• Dosage: The dosing schedule for children is identical to that for adults, as the immune system's response to the allergen is not strictly weight-dependent. However, smaller volumes may be used initially to monitor for local reactions.
• Age Restrictions: Immunotherapy is rarely started in children under the age of 5 due to the difficulty of communicating systemic symptoms (like itchy throat or chest tightness).

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the systemic load of the protein extract is extremely low.

Hepatic Impairment

No specific dosage adjustments are recommended. The metabolism of fungal proteins is not primarily dependent on hepatic CYP450 enzymes.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The risk of using epinephrine (the treatment for anaphylaxis) in these patients must be weighed against the benefits of immunotherapy.

• Administration: This medication must ONLY be administered by a healthcare professional in a clinical setting equipped to treat anaphylaxis. It is given via subcutaneous injection (usually in the back of the upper arm).
• Observation: Patients MUST remain in the clinic for at least 30 minutes after every injection to monitor for life-threatening systemic reactions.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Freezing can denature the proteins and render the extract ineffective or dangerous.
• Preparation: Do not shake the vial vigorously; gentle rotation is preferred to avoid foaming of the protein solution.

If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on how much time has passed.

• 1 week late: Repeat the last dose.
• 2-3 weeks late: Reduce the dose by one or two increments.
• Over 4 weeks late: May require restarting at a much lower concentration.

An overdose of allergenic extract (either by volume or by excessive concentration) can lead to severe systemic reactions, including anaphylactic shock.

• Signs: Hives, swelling of the throat, wheezing, low blood pressure, and loss of consciousness.
• Emergency Measures: Immediate administration of intramuscular epinephrine, followed by antihistamines, corticosteroids, and IV fluids. Seek emergency medical care immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or frequency without medical guidance. Immunotherapy is a multi-year commitment.

Most patients undergoing treatment with Chaetomium globosum will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Local Swelling (Wheal): A raised, itchy bump at the injection site. This typically appears within 15-30 minutes and resolves within 24 hours.
• Erythema (Redness): Redness around the injection site that may feel warm to the touch.
• Pruritus (Itching): Intense itching at the site of the injection or the skin testing site.
• Delayed Local Reactions: Swelling and redness that appear 6 to 12 hours after the injection. These can sometimes be large (the size of a baseball) and may require an adjustment in the next dose.

• Fatigue: Many patients report feeling unusually tired for a few hours following an immunotherapy injection.
• Headache: Mild to moderate tension-type headaches.
• Increased Allergic Symptoms: A temporary 'flare' of hay fever symptoms, such as sneezing, runny nose, or itchy eyes, shortly after the injection.

• Lymphadenopathy: Swelling of the lymph nodes near the injection site (e.g., in the armpit).
• Urticaria (Hives): Generalized hives appearing on parts of the body far from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.

> Warning: Stop taking Chaetomium globosum and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis.

• Respiratory Distress: Wheezing, chest tightness, or difficulty breathing. This is especially common in patients with pre-existing asthma.
• Laryngeal Edema: A feeling of a 'lump in the throat,' hoarseness, or difficulty swallowing, indicating airway swelling.
• Hypotension (Shock): Dizziness, fainting, or a rapid, weak pulse caused by a sudden drop in blood pressure.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.
• Generalized Anaphylaxis: A combination of the above symptoms that can progress rapidly to respiratory or cardiac arrest.

There are no known long-term 'toxic' effects of Chaetomium globosum extract, as it is a biological protein. However, the primary long-term risk is the development of new sensitivities or the persistence of local skin changes (granulomas) at the injection site if the extract is injected too superficially. Some patients may develop 'serum sickness-like' reactions (joint pain, fever, rash) if very high doses are given over long periods, though this is extremely rare with modern protocols.

Chaetomium globosum, like all allergenic extracts, carries a significant risk of severe systemic reactions.

FDA-Required Warning Summary:

• Anaphylaxis Risk: This product can cause severe, life-threatening systemic reactions, including anaphylaxis.
• Setting: Injections must only be given in a medical facility with trained staff and equipment for emergency resuscitation.
• Observation: Patients must be observed for at least 30 minutes post-injection.
• Asthma Warning: Patients with unstable or severe asthma are at a significantly higher risk for fatal reactions.
• Beta-Blockers: Patients taking beta-blockers may be resistant to the effects of epinephrine used to treat a reaction.

Report any unusual symptoms to your healthcare provider. Even a 'large' local reaction should be reported, as it may be a precursor to a systemic reaction at the next dose level.

Chaetomium globosum allergenic extract is intended only for use by physicians experienced in the diagnosis and treatment of allergic diseases. Because of the potential for severe allergic reactions, certain precautions are mandatory. Patients should be in stable health at the time of their injection. If you have an active infection, a fever, or an asthma flare-up, your injection should be postponed.

No FDA black box warnings for Chaetomium Globosum. (Note: While many allergenic extracts carry 'boxed' warnings in their package inserts regarding anaphylaxis, they are often classified as 'General Warnings' rather than the specific 'Black Box' format used for synthetic drugs like antidepressants or anticoagulants. However, the clinical severity remains identical to a black box warning.)

• Anaphylaxis Risk: This is the most significant risk. Anaphylaxis can occur even in patients who have previously tolerated the extract for years. There is no way to predict with 100% certainty who will have a reaction.
• Asthma Status: Your asthma must be well-controlled. If your peak flow is significantly below your personal best, do not take the injection. Most fatalities associated with immunotherapy occur in patients with poorly controlled asthma.
• Injection Technique: The extract must be given subcutaneously. Accidental intravenous injection can cause an immediate, catastrophic systemic reaction as the allergen enters the bloodstream directly.
• Extreme Sensitivity: Some patients are 'exquisitely sensitive' and may require a much slower build-up schedule or a lower maintenance dose.

• Pre-Injection Assessment: Your doctor will ask about your current health and any reactions to the previous dose.
• Post-Injection Observation: You must remain in the waiting room for 30 minutes. Do not leave early, as most fatal reactions occur within this window.
• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used before and after the injection to ensure lung function is stable.
• Skin Site Inspection: The injection site will be checked for excessive swelling before you are discharged.

Generally, Chaetomium globosum does not cause sedation. However, if you experience a systemic reaction or receive epinephrine, you should not drive or operate machinery until you have fully recovered and been cleared by a physician.

Alcohol should be avoided for several hours before and after your injection. Alcohol can cause vasodilation (widening of blood vessels), which may increase the rate of allergen absorption and potentially increase the risk or severity of a systemic reaction.

Unlike many medications, there is no 'withdrawal syndrome' associated with stopping Chaetomium globosum. However, if you stop the treatment prematurely, your allergy symptoms will likely return. If you decide to resume treatment after a long break, you cannot start at your previous dose; you must restart the build-up process from a safe, low concentration to avoid anaphylaxis.

> Important: Discuss all your medical conditions with your healthcare provider before starting Chaetomium Globosum. Ensure they are aware of any history of heart disease or severe lung conditions.

There are no drugs that are strictly 'contraindicated' in the sense of a chemical reaction, but there are drugs that make the use of Chaetomium globosum extract unacceptably dangerous:

• Beta-Blockers (e.g., Propranolol, Metoprolol): These medications are used for high blood pressure and heart conditions. They are contraindicated because they block the effects of epinephrine. If you have an anaphylactic reaction to Chaetomium globosum while on a beta-blocker, the standard treatment (epinephrine) may not work, leading to a potentially fatal outcome.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): Some studies suggest that patients on ACE inhibitors may be at a higher risk for more severe systemic reactions during immunotherapy.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of epinephrine (if it needs to be used), leading to a dangerous spike in blood pressure.

• Antihistamines (e.g., Loratadine, Cetirizine): These do not cause a dangerous interaction, but they mask the results of skin tests. You must stop taking most antihistamines for 3 to 7 days before skin testing with Chaetomium globosum.
• Tricyclic Antidepressants (e.g., Amitriptyline): Like antihistamines, these can suppress skin test reactivity for up to 2 weeks, leading to false-negative results.
• Systemic Corticosteroids: Long-term use of oral steroids can suppress the immune response, potentially making immunotherapy less effective, though they do not typically interfere with the immediate 'wheal and flare' of a skin test.

• No direct food-drug interactions exist. However, avoid heavy meals immediately before an injection, as nausea and vomiting can be early signs of anaphylaxis, and a full stomach complicates airway management.
• Alcohol: As mentioned previously, alcohol can increase the risk of a systemic reaction by increasing blood flow and allergen absorption.

• St. John's Wort: May theoretically affect the metabolism of medications used to treat anaphylaxis, though this is not clinically well-documented.
• High-dose Vitamin C: Some evidence suggests very high doses of Vitamin C may have a mild antihistamine effect, which could theoretically interfere with diagnostic skin testing accuracy.

• Skin Tests: Chaetomium globosum will obviously affect the results of other skin tests performed at the same time if a systemic flare occurs.
• Total IgE: Immunotherapy may cause a transient rise in total serum IgE levels before they eventually decline over several years of treatment.

For each major interaction, the management strategy is usually avoidance or temporary discontinuation. For example, the mechanism for beta-blocker interaction is pharmacodynamic (blocking the beta-adrenergic receptors that epinephrine needs to stimulate). The clinical consequence is epinephrine-resistant anaphylaxis. The strategy is to switch the patient to an alternative blood pressure medication (like a Calcium Channel Blocker) before starting immunotherapy.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure or heart rhythm.

• Severe, Uncontrolled Asthma: Patients whose asthma is not stable (e.g., FEV1 consistently below 70% of predicted) should not receive Chaetomium globosum injections. The risk of a fatal bronchospasm during a systemic reaction is too high.
• Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The stress of a potential systemic reaction and the subsequent need for epinephrine could cause further cardiac damage or arrhythmias.
• Beta-Blocker Therapy: As detailed in the interactions section, the inability to treat anaphylaxis effectively with epinephrine makes this an absolute contraindication in most clinical guidelines.
• Hypersensitivity to Excipients: Patients with a known severe allergy to glycerin (found in many extracts) or phenol (used as a preservative) should not use these products.

• Autoimmune Diseases: Conditions like Lupus or Rheumatoid Arthritis require a careful risk-benefit analysis, as immunotherapy stimulates the immune system and could theoretically cause a flare of the underlying autoimmune condition.
• Malignancy: Patients with active cancer are generally not started on immunotherapy, as the immune system is already compromised or highly stressed.
• Severe Psychological Disorders: Because the patient must be able to communicate subtle symptoms of a reaction, those with severe cognitive or psychological impairment may not be suitable candidates.

Chaetomium globosum may show cross-reactivity with other members of the Ascomycota phylum. Patients allergic to Alternaria alternata or Epicoccum nigrum may show positive skin tests to Chaetomium even if they haven't been directly sensitized to it. This is due to shared protein structures (homologous allergens) among different fungal species.

> Important: Your healthcare provider will evaluate your complete medical history, including heart and lung health, before prescribing Chaetomium Globosum.

• Pregnancy Category: Not formally assigned by the FDA for most non-standardized extracts, but generally treated with extreme caution.
• Initiation: Immunotherapy with Chaetomium globosum should NEVER be started during pregnancy. The risk of a systemic reaction causing fetal hypoxia (lack of oxygen) or uterine contractions is too great.
• Maintenance: If a patient is already on a stable maintenance dose and becomes pregnant, the treatment may be continued, but the dose is typically not increased. The risk of continuing is generally considered lower than the risk of the mother having a severe asthma flare-up due to uncontrolled allergies.
• Teratogenicity: There is no evidence that fungal extracts cause birth defects.

Chaetomium globosum extracts are not known to pass into breast milk in any significant quantity. The proteins are large and are likely broken down at the injection site or in the mother's lymphatic system. Breastfeeding is generally considered safe during immunotherapy.

• Approved Age: While there is no strict lower age limit, it is rarely used in children under age 5.
• Growth Effects: There is no evidence that allergenic extracts affect growth or development.
• Benefits: Early immunotherapy in children may prevent the 'allergic march'—the progression from allergic rhinitis to asthma.

• Risks: Patients over age 65 are at a higher risk for complications from immunotherapy due to the higher prevalence of cardiovascular disease and the use of multiple medications (polypharmacy).
• Assessment: A thorough cardiac evaluation is necessary before starting an elderly patient on Chaetomium globosum.

No dosage adjustments are needed. The amount of protein administered is negligible compared to the total protein turnover in the body.

No dosage adjustments are needed. The liver is not the primary organ for the clearance of these injected fungal proteins.

> Important: Special populations require individualized medical assessment. Pregnant patients should consult both their allergist and their obstetrician.

Chaetomium globosum allergenic extract works by inducing a state of 'desensitization' or 'peripheral tolerance.' The primary molecular target is the T-regulatory (Treg) cell. Upon repeated exposure to increasing doses of the fungal antigens, the immune system increases the production of IL-10 and TGF-β. These cytokines suppress the activity of Th2 cells, which are responsible for producing IL-4 and IL-5—the signals that tell B-cells to make IgE. Over time, the B-cells switch from producing IgE to producing IgG4. IgG4 acts as a 'decoy' or 'blocking antibody,' binding to the Chaetomium proteins before they can reach the IgE on the surface of mast cells.

• Dose-Response: There is a clear dose-response relationship; higher maintenance doses are generally more effective than lower doses, but they also carry a higher risk of systemic reactions.
• Time to Onset: Diagnostic skin test results are visible within 15-20 minutes. Therapeutic effects (symptom reduction) typically take 6 to 12 months of consistent treatment to become noticeable.
• Duration of Effect: If a full 3-to-5-year course of immunotherapy is completed, the benefits can last for several years after the injections are stopped.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local Injection) |

| Protein Binding | N/A (Antigen-Antibody Binding) |

| Half-life | Variable (Hours to Days for proteins) |

| Tmax | 15-30 minutes (for local reaction) |

| Metabolism | Proteolysis (Endogenous) |

| Excretion | Renal (Metabolites) |

• Molecular Formula: Complex mixture (N/A) |
• Molecular Weight: Ranges from 10 kDa to >100 kDa (Proteins) |
• Solubility: Soluble in aqueous buffers and 50% glycerin solutions. |
• Structure: The extract contains various proteins (enzymes like proteases), glycoproteins, and cell wall polysaccharides (beta-glucans) derived from the Chaetomium globosum mycelium and spores.

Chaetomium globosum is classified as a Non-Standardized Fungal Allergenic Extract. It is grouped with other fungal extracts like Aspergillus, Penicillium, and Cladosporium. While it has biological similarities to fungi that produce penicillin, it is not used as an antibacterial agent in clinical practice.